Castle Biosciences (CSTL) Investor Presentation - Slideshow

Financial Performance & Guidance - The company delivered strong year-over-year revenue growth, meeting the top end of its guided range, with total test reports delivered in 2022 up by 58% over 2021[5] - Total test reports in 2022 were 44,419, a 58% increase compared to 28,145 in 2021[5, 20] - Revenues in 2022 reached $137 million, up from $94.1 million in 2021[20] - The company anticipates approximately $170 - $180 million in revenue for 2023[20] Market & Pipeline - The estimated U S Total Addressable Market (TAM) for commercially available tests is approximately $8 billion[12] - Tests in the pipeline add an additional estimated ~$3 6 billion to the U S TAM, including $1 9 billion for inflammatory skin disease and $1 7 billion for additional dermatology tests[17] - The company expects to launch an inflammatory skin disease therapy response pipeline test by 2025[27, 113, 133] Clinical Utility & Evidence - A collaborative NCI study is expected to be published, demonstrating higher melanoma-specific survival for patients tested with DecisionDx-Melanoma[13] - Data analysis shows a 21% benefit in overall survival and a 27% benefit in melanoma-specific survival at 3 years for patients tested with DecisionDx-Melanoma compared to untested patients[48] - IDgenetix shows >2 5x improved chance of remission of depression symptoms vs control[89] Strategic Focus - The company is focused on diagnostic support, risk stratification, and therapy response areas along the patient care journey[10, 11] - Key strategic opportunities include Mental Health and Gastrointestinal areas[8, 9] - The company emphasizes continuous evolution & improvement, customer & solution centricity, and exceptional employees[7, 15]